Search Results
The ATLAS Study: A Clinical Trial for Adults with a Confirmed SOD1 Mutation without Symptoms of ALS
Tofersen helps people with ALS caused by an SOD1 mutation
ALS｜Racing Against Time to Treat Amyotrophic Lateral Sclerosis, A Fatal Disease
Lessons Learned From SOD1 ALS Clinical Development: Opportunities for CMT Drug Development
Thoughts on Clinical Trials from the Perspectives of an ALS Center Director
FaTHoM 2023: PRE-SYMPTOMATIC FAMILIAL ALS: The long view to disease prevention, Michael Benatar
Clinical trial data for TKIs in ALK-rearranged NSCLC
Clinical Trials Webinar 2: ALS Clinical Trial Overview
Expanded Access Programs (EAPs) for ALS
ALS: Update in Treatment & Clinical Trials
Why FDA Decision on Tofersen Matters
SOD1 protects neurons from a cycad neurotoxin via the Na⁺/Ca²⁺ exchanger protein NCX1
